Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe

by Vandana Singh, Benzinga Editor

May 2, 2022 9:17 AM | 1 min read |

The European Commission (EC) has approved Myovant Sciences Ltd's MYOV Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer.
This approval was supported by data from the Phase 3 HERO study.
In the HERO study, Orgovyx met the primary endpoint and achieved sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in 96.7% of men, compared with 88.8% of men receiving leuprolide acetate injections, the current standard of care.
Also See: What's Going On With Myovant Sciences Stock Today?
Orgovyx also achieved several key secondary endpoints compared to leuprolide acetate, including suppression of testosterone to castrate levels and profound testosterone suppression.
The FDA approved Orgovyx in December 2020.
Price Action: MYOV shares closed at $9.31 on Friday.

Posted In: Biotech News Health Care Small Cap General Briefs European Medicines Agency

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.